Summary
A small trial in healthy adults linked a combined nitric-oxide and whole-body vibration protocol to short-term increases in blood amyloid-beta and GFAP. The results are consistent with brain-protein redistribution, but do not test an Alzheimer’s treatment.
A small human trial has linked a combination of nitric-oxide-mediated vasodilation and mechanically modulated whole-body vibration to short-term increases in blood levels of amyloid-beta and GFAP, a brain-derived protein. The 29 participants were healthy adults, not people being treated for Alzheimer’s disease. The researchers interpret the blood and MRI changes as consistent with a temporary movement of brain-derived proteins toward the circulation.
The study, published in Nature Communications, tested a physiological response—not a vibrating mattress or a therapy for clearing Alzheimer’s disease from the brain.
What the trial found
In a randomized crossover study, healthy volunteers took part in separate sessions of whole-body vibration and combined vibration with nitric-oxide-mediated vasodilation. The combined protocol was studied in 26 participants; an exploratory session testing nitric oxide alone involved 12. The vibration was modulated in the 22–50 Hz range and was designed to engage Piezo1, a mechanically sensitive channel found in blood-vessel linings. The interventions were carried out under controlled experimental conditions.
After the combined intervention, blood pressure fell by about 15% on average. Blood tests showed increases in amyloid-beta 40 (Aβ40), amyloid-beta 42 (Aβ42) and GFAP after correction for estimated blood dilution. For example, mean serum Aβ40 rose from 38.2 to 50.5 pg/ml, and mean Aβ42 from 2.6 to 3.5 pg/ml. Median GFAP rose from 65.2 to 85.1 pg/ml. The increases in these markers were associated with the size of the blood-pressure reduction. Neurofilament-light and phosphorylated tau-181 did not show significant changes.
MRI also showed changes after the combined protocol: whole-brain T2 dark-fluid signal intensity fell by an average of 4.6%, while the measured volume of extracerebral cerebrospinal fluid increased by 6.5 ml. Signal intensity rose in some venous regions. The researchers interpret the pattern of blood-test and imaging results as consistent with a temporary redistribution of brain proteins and fluid. T2 dark-fluid MRI signals reflect water and macromolecule content; they are not a direct measurement of protein moving out of the brain.
Why the result is not an Alzheimer’s treatment finding
Aβ40 and Aβ42 are amyloid-beta proteins relevant to Alzheimer’s research, but a brief increase in their blood concentrations is not evidence that amyloid deposits in the brain have been removed, or that memory or disease progression has improved. This trial measured acute physiological and biomarker changes in healthy volunteers; it did not test clinical benefit in people with Alzheimer’s disease.
The findings give researchers a human signal to investigate alongside earlier work on blood-vessel tone, mechanical stimulation and brain-fluid transport. The proposed explanation—that the combined intervention temporarily shifts soluble brain-derived proteins toward blood—is an interpretation of the measured changes, rather than a direct observation of clearance through a specific route.
The interventions were reported as tolerable under the study conditions, with no serious adverse events. Some participants reported headache or nausea after nitric oxide administration, and one participant stopped the study after vomiting. The small, healthy-volunteer sample and acute measurements mean the results should be read as early physiological research, not as evidence of a preventive or therapeutic procedure.